Guerbet Korea X-ray contrast agent Lipiodol Ultra (iodized oil), which caused controversy over supply and demand, faced a drug price cut due to the entry into a generic on the 1st of last month. Still, it is understood that the supply is stable so far. In the meantime, Guerbet Korea has been negotiating with the health authorities for reasons such as 'reduced margins due to price hikes for raw material drugs' and 'justice to maintain current drug prices due to application for price adjustment'.

However, in 2020, Dongkook Pharm's Fattiodol, a competitive product with the nature of an alternative drug, obtained approval from the Ministry of Food and Drug Safety and was released, and the generic drug price